---
title: Economic Impact Analysis
description: Evidence-Based Analysis of the Highest-ROI Public Health Intervention in Human History
published: true
tags:
  - economics
  - cost-benefit-analysis
  - public-health
  - peace-dividend
  - roi
  - impact-assessment
  - health-economics
lastFormatted: '2025-10-16T00:00:00.000Z'
lastStyleCheck: '2025-10-16T00:00:00.000Z'
lastParamCheckHash: c6c1adaae3f668e0729df5aa12f73a0ddedccc987de87895bcc8ca8701b1864c
lastInstructionalVoiceHash: b9c8c2b1470bfa6c6b8afc9d3f84774ad579f4f2d4a0111bc3b252770d7966e9
---
```{python}
#| echo: false
from dih_models.parameters import *

```

## Abstract

**Objective**: We evaluate the economic impact and return on investment of reallocating 1% of global military spending ($27.2B annually) to medical research infrastructure through the Decentralized Institutes of Health (DIH) and Decentralized FDA (dFDA) framework.

**Methods**: Using cost-benefit analysis, net present value (NPV) calculations, quality-adjusted life year (QALY) modeling, and incremental cost-effectiveness ratio (ICER) analysis, we assess both conservative (R&D efficiency gains only) and complete (all quantifiable benefits) scenarios. Data sources include SIPRI military expenditure database, WHO mortality statistics, Oxford RECOVERY trial results, and published clinical trial cost literature.

**Results**: Conservative analysis yields 463:1 ROI ($249.3B NPV benefit / $538M implementation cost) over 10 years, based solely on R&D cost reductions. Complete analysis including peace dividend and seven additional benefit categories demonstrates 1,239:1 ROI ($1.2T annual benefits). The intervention generates 840,000 QALYs annually with negative ICER (-$59,476/QALY), qualifying as a dominant health intervention. Sensitivity analysis shows robust returns across scenarios (66:1 worst-case to 2,577:1 best-case).

**Conclusions**: Redirecting 1% of military spending to medical research infrastructure represents a dominant health intervention, simultaneously reducing costs while improving health outcomes, with ROI exceeding history's most successful public health achievements including smallpox eradication. The self-funding structure eliminates traditional barriers to scale, generating sufficient economic surplus to sustain operations without ongoing charitable contributions.

**Keywords**: cost-benefit analysis, health economics, clinical trials, return on investment, QALY, dominant intervention, peace dividend, global health policy

---

::: {.callout-note}
## Key Findings

1. **Conservative ROI**: {{< var roi_dfda_savings_only >}}:1 return based solely on R&D efficiency gains (${{< var dfda_npv_benefit >}}B NPV benefit / ${{< var dfda_npv_total_cost >}}B implementation cost over 10 years)

2. **Complete ROI**: {{< var roi_all_direct_benefits >}}:1 return including all eight quantifiable benefit categories (${{< var treaty_complete_case_annual_benefits >}}B annual benefits / ${{< var treaty_campaign_total_cost >}}B campaign cost)

3. **Self-Funding**: Zero net new spending required - funds redirected from existing military budgets (${{< var treaty_annual_funding >}}B annually from 1% of ${{< var global_military_spending_annual_2024 >}}B global military spending)

4. **Lives Saved**: {{< var treaty_total_lives_saved_annual >}} lives saved annually at net societal benefit of ${{< var net_benefit_per_life_saved >}}M per life

5. **Dominant Intervention**: Negative ICER (${{< var dfda_icer_per_qaly >}}/QALY) indicates cost savings while improving health - exceeds all traditional health interventions including smallpox eradication (209:1 ROI), polio vaccination (27:1), and measles vaccination (16:1)

6. **Research Acceleration**: {{< var research_acceleration_multiplier >}}× increase in research throughput through dramatically reduced trial costs and increased participation

7. **Robust Returns**: Sensitivity analysis demonstrates positive ROI across all scenarios - worst case 66:1, optimistic case 2,577:1
:::

---

## Research Hypothesis

**Primary Hypothesis**: Reallocating 1% of global military spending (${{< var treaty_annual_funding >}}B annually) to medical research infrastructure (Decentralized Institutes of Health and Decentralized FDA) generates return on investment between 463:1 (conservative estimate, R&D savings only) and 1,239:1 (complete estimate, including peace dividend and all direct benefits), representing a dominant health intervention that simultaneously reduces costs while improving health outcomes.

**Null Hypothesis (H₀)**: The intervention does not generate positive net economic value (ROI ≤ 1:1)

**Alternative Hypothesis (H₁)**: The intervention generates substantial positive returns (ROI > 1:1), comparable to or exceeding history's most successful public health interventions (smallpox eradication: 209:1, polio vaccination: 27:1, measles vaccination: 16:1)

**Testable Predictions**:
- Conservative case: NPV benefit exceeds $100B over 10-year horizon
- Cost-effectiveness: ICER < $0/QALY (cost-saving while improving health)
- Research acceleration: >10× increase in trial completion rates
- Self-funding threshold: Annual benefits exceed annual costs by year 3 of implementation

---

::: {.callout-tip collapse="true"}
## Nomenclature and Key Terms

**NPV (Net Present Value)**: Economic metric that discounts future cash flows to present-day values, accounting for the time value of money. Used to compare costs and benefits occurring at different times.

**QALY (Quality-Adjusted Life Year)**: Standard health economics measure combining quantity and quality of life. One QALY = one year of life in perfect health. Used to compare health interventions across different conditions.

**ICER (Incremental Cost-Effectiveness Ratio)**: Cost per QALY gained, calculated as (Cost_intervention - Cost_baseline) / (QALY_intervention - QALY_baseline). Negative ICER indicates cost savings while improving health (dominant intervention).

**ROI (Return on Investment)**: Ratio of net benefits to costs. Calculated as NPV(Benefits) / NPV(Costs) for time-adjusted analysis, or Annual Benefits / Annual Costs for simple analysis.

**dFDA (Decentralized FDA)**: Proposed system for conducting clinical trials using real-world data, electronic health records, and decentralized patient participation. Reduces per-patient costs by 50-95% compared to traditional trials.

**DIH (Decentralized Institutes of Health)**: Proposed global research infrastructure funded by 1% of military spending reallocation, coordinating decentralized clinical trials and medical research.

**Peace Dividend**: Economic benefits from reduced military spending, including fiscal savings, reduced conflict-related economic damage, and favorable economic multiplier effects from reallocating resources to productive sectors.

**Dominant Intervention**: Health economics term for interventions that both reduce costs AND improve health outcomes. Unconditionally recommended regardless of willingness-to-pay thresholds (e.g., vaccination programs, smoking cessation).

**1% Treaty**: Proposed international agreement where signatory nations commit to reducing military expenditure by 1% and redirecting those funds (${{< var treaty_annual_funding >}}B globally) to medical research infrastructure.

**Pragmatic Clinical Trial**: Trial design using real-world settings and broad eligibility criteria rather than highly controlled laboratory conditions. Reduces costs while improving generalizability (e.g., Oxford RECOVERY trial).
:::

---

**The Highest-ROI Public Health Intervention Ever Proposed**

**Shift 1% of global military spending into decentralized clinical trials.

Accelerate medical progress {{< var research_acceleration_multiplier >}}×.
Save trillions annually.
Prevent millions of deaths.
Strengthen national security.
And finance it using self-interest.**

Humanity spends **{{< var global_military_spending_annual_2024 >}} per year** developing better ways to damage itself, and **{{< var global_med_research_spending >}} billion per year** developing better ways to heal itself.

This is a **{{< var military_vs_medical_research_ratio >}} misallocation** of resources relative to our actual goals:
less disease, more life, more prosperity, fewer funerals.

The solution is mathematically straightforward:

> **Move 1% of the “making corpses” budget into the “preventing corpses” budget.**
> No new taxes.
> No cuts to social programs.
> No trade-offs.
> Just 1% less global self-harm.

---

# **The Result**

### **{{< var roi_dfda_savings_only >}}:1 to 1,239:1 ROI**

### **{{< var research_acceleration_multiplier >}}× faster medical progress**

### **The equivalent of 2,000 years of medical advancement in 20 years**

### **9.1 trillion hours of unnecessary human suffering eliminated annually**

### **20–60 million life-years saved per billion dollars invested**

### **Money saved: {{< var peace_dividend_annual_societal_benefit >}} + $50–100B per year**

These figures are conservative and based on real-world results:

* **Oxford RECOVERY** showed trials can be **{{< var trial_cost_reduction_factor >}}× cheaper** when stripped to scientific essentials.
* This method produced **the most important COVID discoveries**—faster than any bureaucracy in history.
* The limiting factor is not scientific knowledge.
* The limiting factor is **administrative friction**.

Right now, medical progress flows through a soda straw.
A 1% shift makes it a **fire hose**.

---

# **Why 1% Is Enough**

### **1. The Peace Dividend: {{< var peace_dividend_annual_societal_benefit >}}/year saved**

Even a 1% reduction in global weapons procurement yields massive savings.
Bombs are expensive, and breaking things is not free to repair.

### **2. The Research Efficiency Dividend: {{< var dfda_gross_savings_annual >}}–$100B/year saved**

Pragmatic trials eliminate:

* bespoke infrastructure
* redundant data collection
* high-cost monitoring
* regulatory overproduction
* 17 years of unnecessary documentation

This is why costs fall **{{< var trial_cost_reduction_factor >}}×**, not 2× or 5×.

### **3. 15–40 “NIH equivalents” of new research capacity**

For the first time, humanity would fund medical progress **faster than disease progression**, reversing a century-long imbalance.

---

# **And It Strengthens National Security**

A 1% coordinated shift **does not change**:

* relative power balances
* deterrence
* force ratios
* strategic stability
* readiness
* cyber capabilities
* troop projection
* nuclear deterrence posture

But it **does** reduce existential risk:

* fewer deployed warheads
* lower accidental-launch probability
* reduced crisis instability
* fewer escalatory supply-chain pressures

A safer world with the same level of deterrence is strictly better.

This is one of the only reforms that is **pro-security and pro-survival** simultaneously.

---

# **Why This Works: The Political Economy (The Real Bottleneck)**

Good ideas don’t win by being good.
Good ideas win by **aligning incentives**.

Here is the alignment engine:

---

# **Victory Social Impact Bonds: The Greed-Aligned Engine That Makes This Pass**

The plan succeeds because **investors profit** from the cost savings generated by the 1% shift.

### **This is how it works:**

1. Investors buy **Victory Social Impact Bonds**.
2. Funds are used to run the **most effective lobbying campaign in modern history**, aimed at redirecting 1% of global military spending into medical research.
3. When the reform passes, governments save **hundreds of billions** (peace dividend + research-efficiency dividend).
4. A portion of these savings repays investors with strong returns.
5. Investors, therefore, fund the campaign that causes their own returns.

This is **public choice theory applied correctly**:
Self-interest becomes a public good.

No one has to become a better person for this to work.
They just have to follow incentives.

{{< include ../figures/victory-bonds-money-flow-diagram.qmd >}}

# **The Complete, Causal Roadmap (How It Actually Passes)**

This is not utopian. It is a mechanical sequence:

### **Step 1 — Global Survey on Human Values**

Demonstrate overwhelming global public support for medical acceleration and reduced suffering.
This creates legitimacy and media momentum.

### **Step 2 — Hit the {{< var global_population_activism_threshold_pct >}} Tipping Point**

Social-movement science shows that **{{< var global_population_activism_threshold_pct >}} committed support** reliably precedes policy adoption.
This is the activation threshold.

### **Step 3 — Assemble the Investor Coalition**

Victory Bond investors fund the lobbying campaign because the reform pays for itself many times over.

### **Step 4 — Execute the Most Cost-Effective Lobbying Campaign Possible**

Lobbyists and political strategists deploy Victory Bond funds to pass 1% military reallocation legislation.
This is standard political action, just pointed at saving lives instead of making weapons.

### **Step 5 — Deploy Funds Through the Decentralized FDA (dFDA)**

The 1% shift becomes **infinitely scalable, automated pragmatic trials**.
Thousands of long-tail treatments finally get tested.
Effective ones instantly scale.

### **Step 6 — Civilization Enters the Medical Singularity Phase**

{{< var research_acceleration_multiplier >}}× acceleration.
Disease categories collapse.
Healthspan overtakes pathology.
Investors profit.
Governments save money.
The world becomes healthier, safer, and richer.
Everyone wins.

A plan is credible not because it is idealistic, but because **every step is economically rational for every participating actor**.

---

# **Why This Is the Dominant Strategy for Civilization**

If your goal is to maximize:

* QALYs
* DALYs averted
* lifespan
* productivity
* economic growth
* national security
* existential safety
* reduction in human suffering

…then this is not merely a good policy.
It is the **mathematically dominant strategy**.

A $1B investment yields:

* more health
* more survival
* more stability
* more prosperity
* more innovation
* more safety

than any other use of $1B known in public policy, philanthropy, global health, or defense.

No bed net.
No vaccine.
No research initiative.
No climate intervention.
No economic reform.
No AI safety lab.
No global treaty.

All are valuable.
None offer **{{< var research_acceleration_multiplier >}}× leverage**.

---

# Methodology and Analytical Framework

This analysis employs standard health economics methodologies to evaluate the economic impact of reallocating 1% of global military spending to medical research infrastructure. The analytical framework integrates cost-benefit analysis, quality-adjusted life year (QALY) modeling, and net present value (NPV) calculations to assess both conservative and complete scenarios.

## Cost-Benefit Analysis Framework

### Net Present Value (NPV) Methodology

The analysis uses net present value calculations to account for the time value of money over a 10-year time horizon. The NPV framework discounts future costs and benefits to present-day values using a standard {{< var npv_discount_rate_standard >}} annual discount rate.

**NPV of Costs:**

$$
\text{NPV}(\text{Costs}) = C_{0} + \sum_{t=1}^{T} \frac{C_{\text{op}}(t)}{(1 + r)^t}
$$

where $C_{0}$ represents initial upfront costs (platform development, legal frameworks, data integration), $C_{\text{op}}(t)$ represents annual operating costs in year $t$ (maintenance, analysis, administration), $r$ is the discount rate ({{< var npv_discount_rate_standard >}}), and $T$ is the time horizon ({{< var npv_time_horizon_years >}} years).

**NPV of Benefits:**

Annual benefits $S(t)$ are calculated as:

$$
S(t) = p(t)\alpha R_{d}
$$

where $p(t)$ represents the adoption rate at year $t$ (modeled as gradual ramp-up over {{< var dfda_npv_adoption_ramp_years >}} years), $\alpha$ represents the fraction of R&D costs saved ({{< var trial_cost_reduction_pct >}} baseline scenario), and $R_{d}$ represents annual global clinical trial expenditure ({{< var global_clinical_trials_spending_annual >}}).

The NPV of benefits is:

$$
\text{NPV}(\text{Benefits}) = \sum_{t=1}^{T} \frac{S(t)}{(1 + r)^t}
$$

**Return on Investment (ROI):**

$$
\text{ROI} = \frac{\text{NPV}(\text{Benefits})}{\text{NPV}(\text{Costs})}
$$

This methodology provides the conservative estimate of {{< var roi_dfda_savings_only >}}:1 ROI over the {{< var npv_time_horizon_years >}}-year time horizon.

### Cost-Effectiveness Analysis: ICER Framework

The Incremental Cost-Effectiveness Ratio (ICER) measures cost per quality-adjusted life year (QALY) gained:

$$
\text{ICER} = \frac{\Delta \text{Cost}}{\Delta \text{QALYs}} = \frac{C_{\text{intervention}} - C_{\text{baseline}}}{Q_{\text{intervention}} - Q_{\text{baseline}}}
$$

For the dFDA infrastructure (using annual figures):

```{python}
#| echo: false
from dih_models.parameters import *
from IPython.display import display, Markdown

icer_eq = f"$$\\text{{ICER}} = \\frac{{\\text{{Net Incremental Cost (Annual)}}}}{{\\text{{QALYs Gained (Annual)}}}} = \\frac{{-\\$49.96\\text{{B}}}}{{{GLOBAL_DFDA_QALYS_GAINED_ANNUAL:,} \\text{{ QALYs}}}} = -\\$59{{,}}476 \\text{{ per QALY}}$$"
display(Markdown(icer_eq))
```

The negative ICER indicates cost savings while improving health, a **dominant intervention** by health economics standards. Standard willingness-to-pay thresholds are {{< var qalys_from_prevention_conservative >}}-{{< var standard_economic_qaly_value_usd >}} per QALY; interventions that save costs while gaining QALYs are unconditionally recommended.

## Quality-Adjusted Life Year (QALY) Valuation

QALYs represent the standard metric in health economics for comparing health interventions across different conditions and treatment modalities. One QALY equals one year of life in perfect health.

### QALY Calculation Model

The total annual QALY gain ({{< var global_dfda_qalys_gained_annual >}} QALYs baseline) derives from three distinct benefit streams:

**A. Accelerated Development of Existing Pipeline Drugs**

Health gains from bringing effective treatments to patients faster through shortened development and approval timelines:

- **Baseline:** Research shows one-year delays in cancer therapy diffusion resulted in 84,000 life-years lost
- **Estimate:** 2-year average acceleration across pharmaceutical pipeline
- **Annual QALYs:** 180,000-500,000 QALYs (baseline: 24% of total)

**B. Improved Preventative Care via Real-World Evidence**

Value of using comprehensive data to optimize preventative care and treatment effectiveness:

- **Baseline:** Cancer screenings alone have saved millions of life-years; significant untapped potential remains
- **Mechanism:** Large-scale identification of at-risk populations and real-world effectiveness measurement
- **Annual QALYs:** {{< var qalys_from_prevention_conservative >}}-{{< var qalys_from_prevention_optimistic >}} QALYs (baseline: 17% of total)

**C. Enabling Research for Previously Untreatable Diseases**

Transformative potential to create viable research pathways for conditions ignored due to high trial costs:

- **Baseline:** {{< var rare_diseases_count_global >}}+ rare diseases, {{< var dfda_trial_completion_rate >}} lack FDA-approved treatments
- **Mechanism:** Radically lower per-patient costs make rare disease R&D economically feasible
- **Annual QALYs:** {{< var qalys_from_prevention_conservative >}}-{{< var qalys_from_new_therapies_optimistic >}} QALYs (baseline: 60% of total)

**QALY Valuation:** Standard economic valuations range from ${{< var qalys_from_prevention_conservative >}}-${{< var standard_economic_qaly_value_usd >}} per QALY. This analysis uses conservative mid-range values.

For detailed QALY calculation methodology, see [dFDA QALY Model](../appendix/dfda-qaly-model.qmd).

## Peace Dividend Calculation Methodology

The peace dividend represents economic benefits from reduced military spending. The {{< var treaty_reduction_pct >}} Treaty redirects {{< var treaty_reduction_pct >}} of global military spending (${{< var global_military_spending_annual_2024 >}}B in 2024) = ${{< var treaty_annual_funding >}}B annually.

**Economic benefits of reduced military spending:**

1. **Direct fiscal savings:** {{< var treaty_annual_funding >}} available for productive investment
2. **Reduced conflict-related economic damage:** Historical analysis shows military spending reductions correlate with decreased trade disruption, infrastructure destruction, and refugee costs
3. **Economic multiplier effects:** Reallocation from military to medical research generates higher economic returns (medical research multiplier: 2.0-3.0×; military spending multiplier: 0.5-1.0×)

**Conservative estimate:** Analysis uses {{< var peace_dividend_annual_societal_benefit >}} annual peace dividend based on World Bank and IMF frameworks for economic benefits of reduced military expenditure.

For detailed calculations, see [Peace Dividend Analysis](../appendix/peace-dividend-calculations.qmd).

## Research Acceleration Mechanism

The {{< var research_acceleration_multiplier >}}× research acceleration multiplier derives from specific, measurable improvements across four dimensions:

| Factor | Current System | dFDA System | Multiplier |
|:---|---:|---:|---:|
| **Recruitment Speed** | 6-18 months for 100 patients | 3 weeks for {{< var traditional_large_trial_size >}} patients | **25×** |
| **Trial Completion Speed** | 3-5 years | 3-12 months | **10×** |
| **Simultaneous Trials** | {{< var current_active_trials >}} active trials | {{< var dfda_active_trials >}} active trials | **20×** |
| **Completion Rate** | {{< var current_trials_per_year >}} finish | {{< var dfda_trial_completion_rate >}} finish | **1.6×** |
| **Funding Increase** | ${{< var global_med_research_spending >}}B baseline | $94.7B (baseline + {{< var treaty_annual_funding >}}B) | **1.4×** |

**Theoretical maximum:** 25 × 10 × 1.6 × 1.4 = 560×

**Conservative application:** Analysis uses {{< var research_acceleration_multiplier >}}× multiplier accounting for implementation constraints, regulatory requirements, and gradual adoption.

For detailed derivation, see [Research Acceleration Model](../appendix/research-acceleration-model.qmd).

## Data Sources and Primary Inputs

**Military and Conflict Data:**
- Global military spending: [SIPRI Military Expenditure Database](../references.qmd#sipri-2024) ({{< var global_military_spending_annual_2024 >}}B annually)
- Conflict deaths: [Armed Conflict Location & Event Data Project (ACLED)](../references.qmd#acled-2024), [Global Terrorism Database (GTD)](../references.qmd#gtd-2024), [Uppsala Conflict Data Program (UCDP)](../references.qmd#ucdp-2024)

**Clinical Trial Economics:**
- Global trial market: [Global Clinical Trials Market Report 2024](../references.qmd#global-clinical-trials-market-2024) ({{< var global_clinical_trials_spending_annual >}} annually)
- Cost reduction benchmarks: [Oxford RECOVERY Trial](../appendix/recovery-trial.qmd) ({{< var trial_cost_reduction_factor >}}× cost reduction demonstrated)
- Trial completion rates: [ClinicalTrials.gov database](../references.qmd#clinicaltrials-gov) ({{< var current_trials_per_year >}} trials initiated annually, {{< var current_trial_abandonment_rate >}} completion rate)

**Health Economics:**
- QALY valuations: [ICER QALY Methodology](../references.qmd#icer-qaly-methodology), NBER working papers (Glied & Lleras-Muney, Philipson et al.)
- Disease burden: [WHO Global Health Observatory](../references.qmd#who-mortality-data)
- Rare diseases: [National Organization for Rare Disorders (NORD)](../references.qmd#rare-disease-patients-300m-globally)

**Economic Parameters:**
- Discount rate: {{< var npv_discount_rate_standard >}} (standard health economics practice)
- Time horizon: {{< var npv_time_horizon_years >}} years (standard for infrastructure investments)
- Value of statistical life: ${{< var value_of_statistical_life >}}M (EPA/DOT standard)

All data sources include confidence levels and last-update dates. See [References](../references.qmd) for complete bibliography.

## Sensitivity Analysis Approach

The analysis employs comprehensive sensitivity testing across multiple scenarios to assess robustness of findings:

**Conservative Scenario ({{< var roi_dfda_savings_only >}}:1 ROI):**
- R&D cost reduction: {{< var trial_cost_reduction_pct >}}
- QALY gains: {{< var qalys_total_conservative >}} annually
- Adoption timeline: {{< var dfda_npv_adoption_ramp_years >}} years to full adoption
- Includes only R&D efficiency savings (excludes peace dividend and six additional benefit categories)

**Worst-Case Scenario (66:1 ROI):**
- Benefits half as good as baseline
- Costs twice as high as baseline
- Extended adoption timeline
- Regulatory barriers and implementation delays

**Optimistic Scenario (2,577:1 ROI):**
- R&D cost reduction: {{< var trial_cost_reduction_pct >}} (RECOVERY trial-like efficiency)
- QALY gains: {{< var qalys_total_optimistic >}} annually
- Faster adoption and broader scope

**Complete Case (1,239:1 ROI):**
- Includes all eight quantifiable benefit categories
- Peace dividend: ${{< var peace_dividend_annual_societal_benefit >}}
- Earlier treatment access, research acceleration, rare disease treatments, drug price reductions, prevention medicine, mental health benefits

Sensitivity analysis demonstrates robust returns across all scenarios, with ROI ranging from 66:1 (worst-case) to 2,577:1 (optimistic). See [1% Treaty Cost-Effectiveness Analysis](../appendix/1-percent-treaty-cost-effectiveness.qmd) for detailed scenario modeling.

## Key Analytical Assumptions

This analysis rests on several core assumptions that should be made explicit for academic transparency:

### Strategic Stability Assumption

**Assumption:** A coordinated {{< var treaty_reduction_pct >}} reduction in military spending across all nations maintains relative power balances and strategic deterrence capabilities.

**Justification:** The {{< var treaty_reduction_pct >}} Treaty explicitly requires proportional reductions from all signatories. Since relative military capabilities remain unchanged, strategic stability is preserved. Historical analysis shows that symmetric reductions in military tensions (e.g., START treaties, naval treaties between world wars) maintained deterrence while reducing absolute expenditure.

**Sensitivity:** This assumption is critical to the peace dividend calculation. Alternative scenarios modeling unilateral reductions would require different political economy frameworks.

### Linear Scaling Assumption

**Assumption:** Economic benefits and costs scale approximately linearly with program scope and adoption rates.

**Justification:** Conservative assumption that costs scale with system usage. Research acceleration benefits may exhibit superlinear returns (network effects, data abundance), making this assumption conservative.

**Sensitivity:** Tested through worst-case (66:1 ROI) and optimistic (2,577:1 ROI) scenarios spanning benefits 50% lower to 5× higher than baseline.

### Adoption Rate Assumptions

**Assumption:** dFDA achieves gradual adoption following a {{< var dfda_npv_adoption_ramp_years >}}-year linear ramp to 50%-80% participation rate among eligible trials.

**Conservative case:** 50% of trials adopt dFDA methodology
**Optimistic case:** 80% adoption rate

**Justification:** Based on historical adoption curves for electronic health records (5-10 years to majority adoption), clinical trial registry systems, and FDA Sentinel System implementation.

**Sensitivity:** NPV calculations explicitly model adoption uncertainty through gradual ramp-up rather than immediate full adoption.

### Cost Reduction Assumptions

**Assumption:** dFDA methodology reduces per-patient trial costs by {{< var trial_cost_reduction_pct >}} (conservative) to 95% (optimistic) compared to traditional randomized controlled trials.

**Empirical basis:**
- Oxford RECOVERY trial: {{< var trial_cost_reduction_factor >}}× cost reduction (${{< var recovery_trial_cost_per_patient >}} per patient vs. ${{< var traditional_phase3_cost_per_patient >}} traditional)
- ADAPTABLE trial: Similar cost structure using pragmatic design
- Literature on pragmatic trials consistently shows 50-95% cost reductions

**Sensitivity:** Conservative scenario ({{< var roi_dfda_savings_only >}}:1 ROI) uses {{< var trial_cost_reduction_pct >}} reduction; optimistic case uses 95%.

### Political Feasibility Assumption

**Assumption:** The {{< var treaty_reduction_pct >}} Treaty achieves ratification by sufficient nations within a 3-5 year campaign timeline.

**Justification:** Historical treaty adoption timelines vary (Nuclear Non-Proliferation Treaty: 3 years; Paris Climate Agreement: 5 years). This analysis focuses on economic value *conditional* on implementation, not probability of political success.

**Important caveat:** This analysis does not model the probability distribution over political outcomes. The economic case (463:1 to 1,239:1 ROI) holds *if implemented*, but political economy barriers to implementation are substantial and outside the scope of this cost-benefit analysis.

### Technology Constancy Assumption

**Assumption:** Analysis does not incorporate potential advances in AI, automation, or biotechnology that could further accelerate research.

**Justification:** Conservative assumption. Emerging AI capabilities in drug discovery, automated synthesis, and computational biology could dramatically increase research productivity beyond modeled estimates.

**Implication:** Baseline estimates likely underestimate long-term benefits by excluding technology-driven accelerations.

### Data Quality and Availability

All primary data sources are documented in [References](../references.qmd) with confidence levels:
- **High confidence** (78%): SIPRI military expenditure, WHO mortality statistics, ClinicalTrials.gov data
- **Medium confidence** (17%): Peace dividend estimates, QALY valuations (wide range in literature)
- **Conservative bounds**: Where uncertainty exists, analysis uses conservative estimates favoring underestimation of benefits

For complete parameter documentation with confidence indicators and peer-review status, see [Parameters and Calculations Reference](../appendix/parameters-and-calculations.qmd).

---

# The Conservative Case: {{< var roi_dfda_savings_only >}} ROI (dFDA Only)

Here's the floor. Count only R&D savings from cheaper trials. Ignore peace dividends, earlier access, and everything else that makes this look "too good to be true."

### The Math

Basic division:

$$
\text{ROI} = \frac{\text{Benefits}}{\text{Costs}} = \frac{\$249.3\text{B}}{\$538\text{M}} = 463:1
$$

where {{< var dfda_npv_net_benefit_conservative >}} is what you save over 10 years and {{< var dfda_npv_total_cost >}} is what you spend to build it.

This uses "net present value" which is economist code for "future money is worth less than current money" ({{< var dfda_trial_abandonment_rate >}} discount rate, 10-year horizon). For the spreadsheet addicts: [full NPV methodology here](../appendix/dfda-cost-benefit-analysis.qmd#calculation-framework---npv-methodology).

### Where the Money Comes From

{{< var treaty_reduction_pct >}} of global military budgets gets redirected. This gives you:

- **Funding**: {{< var global_annual_human_cost_state_violence >}}/year to spend on not-dying
- **Bonus savings**: {{< var peace_dividend_annual_societal_benefit >}}/year in economic value from building 1% fewer things that explode

The peace dividend math is simple: wars cost {{< var global_annual_war_total_cost >}}/year. {{< var treaty_reduction_pct >}} less war costs {{< var treaty_reduction_pct >}} less money.

$$
\$11{,}355\text{B} \times 1\% = \$113.6\text{B}
$$

| Cost Category | Annual Amount | Components |
|:---|---:|:---|
| **Direct Military Spending** | [$2,718B](../references.qmd#sipri-2024-spending) | SIPRI 2024 global military budgets |
| **[Infrastructure Destruction](../appendix/peace-dividend-calculations.qmd)** | [$1,875B](../appendix/peace-dividend-calculations.qmd) | Transportation, energy, communications, water, education, healthcare facilities |
| **Human Life Losses** | [$2,446B](../appendix/peace-dividend-calculations.qmd) | {{< var global_annual_conflict_deaths_total >}} conflict deaths × {{< var value_of_statistical_life >}} value of statistical life (conservative vs. DOT $13.7M) |
| **[Trade Disruption](../appendix/peace-dividend-calculations.qmd)** | {{< var global_annual_trade_disruption_conflict >}} | Shipping, supply chains, energy prices, currency volatility |
| **[Lost Economic Growth](../appendix/peace-dividend-calculations.qmd)** | [$2,718B](../appendix/peace-dividend-calculations.qmd) | Opportunity cost of military spending vs. productive investment |
| **[Veteran Healthcare](../appendix/peace-dividend-calculations.qmd)** | {{< var sensitivity_peace_dividend_optimistic >}} | Long-term medical care for conflict-related injuries |
| **Refugee Support** | {{< var global_annual_refugee_support_costs >}} | [108.4M displaced persons](../references.qmd#unhcr-forcibly-displaced-2023) × $1,384/year |
| **[Environmental Damage](../appendix/peace-dividend-calculations.qmd)** | {{< var global_clinical_trial_market_annual >}} | Environmental destruction, toxic contamination, restoration costs |
| **[Psychological Impact](../appendix/peace-dividend-calculations.qmd)** | {{< var global_annual_psychological_impact_costs_conflict >}} | PTSD treatment, mental health services, productivity loss |
| **[Lost Human Capital](../appendix/peace-dividend-calculations.qmd)** | {{< var global_annual_lost_human_capital_conflict >}} | Productive capacity lost from casualties and displacement |
| **Total War Costs** | **$11,355B** | Combined direct and indirect annual costs |
| **1% Reduction** | **{{< var peace_dividend_annual_societal_benefit >}}** | Peace dividend from 1% treaty implementation |

This calculation methodology follows standard cost-of-conflict analysis frameworks used by the World Bank, IMF, and academic conflict economics research. See [Peace Dividend Calculations](../appendix/peace-dividend-calculations.qmd) for detailed sources and methodology.

{{< include ../figures/peace-dividend-breakdown-bar-chart.qmd >}}

### What It Costs to Build

**Total**: {{< var dfda_npv_total_cost >}} over 10 years (present value)
  - Upfront: {{< var dfda_npv_upfront_cost_total >}} (build the platform)
  - Yearly operations: {{< var dfda_upfront_build >}} (keep it running)

The [$27.2B/year](../appendix/peace-dividend-calculations.qmd) peace dividend covers {{< var dfda_upfront_build >}}/year operations **680 times over**. It's like having $680 to pay a $1 bill.

This assumes gradual rollout (0% to {{< var peace_dividend_environmental >}} over 5 years) and middle-range costs. For the detailed breakdown see [dFDA Cost-Benefit Analysis](../appendix/dfda-cost-benefit-analysis.qmd#costs-of-building-and-operating-the-global-decentralized-fda-rom-estimate).

### What You Get Back

- **Money**: {{< var global_annual_trade_disruption_shipping_conflict >}} in R&D savings (10 years, present value)
- **Returns**: {{< var dfda_npv_net_benefit_conservative >}} ÷ {{< var dfda_npv_total_cost >}} = **[463:1](../appendix/dfda-cost-benefit-analysis.qmd)**
- **People not dying**: {{< var global_dfda_qalys_gained_annual >}} quality-adjusted life years annually

**Two income streams from one budget shift**:

1. **Peace dividend**: {{< var peace_dividend_annual_societal_benefit >}}/year saved by not breaking as much stuff
2. **Research efficiency**: {{< var current_drug_approvals_per_year >}}/year saved by not requiring PhDs to fill out forms for 17 years

**Combined**: {{< var combined_peace_health_dividends_annual_for_roi_calc >}}/year (conservative, ignoring most benefits)

**If everything goes wrong**: Worst-case scenario (benefits half as good, costs twice as high) still delivers 189:1 to {{< var optimistic_scenario_roi >}}:1 returns. See [sensitivity analysis](../appendix/1-percent-treaty-cost-effectiveness.qmd).

{{< include ../figures/dfda-roi-sensitivity-analysis-column-chart.qmd >}}

### Cost-Effectiveness: Dominant Health Intervention

Unlike traditional public health interventions that require ongoing funding, the {{< var treaty_reduction_pct >}} Treaty represents a **dominant intervention**, simultaneously reducing costs while improving health outcomes. This places it in a unique category alongside smallpox eradication and other transformative health achievements.

#### Incremental Cost-Effectiveness Ratio (ICER)

The ICER measures cost per quality-adjusted life year (QALY) gained:

$$
\text{ICER} = \frac{\Delta \text{Cost}}{\Delta \text{QALYs}} = \frac{C_{\text{intervention}} - C_{\text{baseline}}}{Q_{\text{intervention}} - Q_{\text{baseline}}}
$$

For the dFDA Infrastructure (using annual figures):

$$
\text{ICER} = \frac{\text{Net Incremental Cost (Annual)}}{\text{QALYs Gained (Annual)}} = \frac{-\$49.96\text{B}}{840{,}000 \text{ QALYs}} = -\$59{,}476 \text{ per QALY}
$$

where the net incremental cost is calculated as platform operational costs ({{< var dfda_upfront_build >}}/year) minus R&D savings ([$50.0B/year](../appendix/dfda-cost-benefit-analysis.qmd)) = -$49.96B annually, and {{< var global_dfda_qalys_gained_annual >}} QALYs represents annual quality-adjusted life years gained.

The negative ICER indicates **cost savings while improving health**, a dominant intervention by health economics standards. Standard willingness-to-pay thresholds are {{< var qalys_from_prevention_conservative >}}-{{< var standard_economic_qaly_value_usd >}} per QALY; interventions that save costs while gaining QALYs are unconditionally recommended.

**For comprehensive ICER analysis including sensitivity analysis across multiple scenarios, alternative funding perspectives, and detailed methodology**, see [dFDA ICER Analysis](../appendix/dfda-cost-benefit-analysis.qmd#dfda-icer-analysis---cost-utility-framework).

#### Comparative Cost per Life Saved

- **[Against Malaria Foundation](../references.qmd#givewell-cost-per-life-saved)**: {{< var givewell_cost_per_life_min >}} cost per life saved (GiveWell top charity)
- **[Deworm the World Initiative](../references.qmd#givewell-cost-per-life-saved)**: {{< var givewell_cost_per_life_max >}} cost per life saved (highly cost-effective intervention)
- **{{< var treaty_reduction_pct >}} Treaty/dFDA System**: [$6,560,000 net societal benefit](../appendix/1-percent-treaty-cost-effectiveness.qmd) per life saved (dominant intervention)

The negative cost (net benefit) per life saved distinguishes this as a dominant intervention in health economics terminology, an intervention that both reduces costs and improves outcomes, with no trade-off between efficiency and effectiveness.

### Self-Funding Mechanism Through Military Budget Redirection

{{< include ../figures/self-funding-roi-comparison-column-chart.qmd >}}

The {{< var treaty_reduction_pct >}} Treaty financing structure creates a self-funding system requiring zero net new spending from donors or taxpayers.

**Economic Structure** ([see detailed calculation](../appendix/1-percent-treaty-cost-effectiveness.qmd)):

- **Funding Source**: [$27.2B annually](../appendix/peace-dividend-calculations.qmd) from 1% redirection of existing military budgets (money already allocated in national budgets)
- **Annual Benefits**: {{< var combined_peace_health_dividends_annual_for_roi_calc >}} (Peace dividend: {{< var peace_dividend_annual_societal_benefit >}} + R&D savings: [$50.0B](../appendix/dfda-cost-benefit-analysis.qmd))
- **Operating Costs**: {{< var treaty_total_annual_costs >}} annually (campaign operations and dFDA infrastructure)
- **Net Position**: {{< var treaty_total_annual_benefits >}} annual surplus after all costs
- **Lives Saved**: {{< var treaty_total_lives_saved_annual >}} annually

$$
925{,}610 \text{ QALYs} \div 35 \text{ QALYs/life} = 26{,}446 \text{ lives}
$$

- **Cost per Life Saved**: Net societal benefit of `{python} cost_per_life_investor_funded_formatted` per life ([negative cost](../appendix/1-percent-treaty-cost-effectiveness.qmd) indicates net profit)

This financing structure classifies the {{< var treaty_reduction_pct >}} Treaty as a **dominant health intervention** using standard health economics terminology, an intervention with both lower costs and better health outcomes than the status quo, requiring no trade-off between cost-effectiveness and impact.

The self-funding nature eliminates traditional barriers to scale, as the intervention generates sufficient economic surplus to sustain and expand operations without ongoing charitable contributions.

# The Complete Case: {{< var roi_all_direct_benefits >}}:1 ROI (All Direct Benefits)

The conservative {{< var roi_dfda_savings_only >}} calculation deliberately excludes most system benefits to establish a defensible floor. A comprehensive analysis including all eight quantifiable primary benefit categories demonstrates substantially higher returns.

### {{< var total_complete_benefits_annual >}} in Annual Benefits

The complete benefit framework encompasses eight measurable categories. Total annual benefit $B_{\text{total}}$ is calculated as:

$$
B_{\text{total}} = \sum_{i=1}^{8} B_i = B_{\text{peace}} + B_{\text{R\&D}} + B_{\text{access}} + B_{\text{research}} + B_{\text{rare}} + B_{\text{prices}} + B_{\text{prevention}} + B_{\text{mental}}
$$

where each benefit category is:

1. **Peace dividend** ({{< var peace_dividend_annual_societal_benefit >}}) - Societal savings from 1% less conflict
2. **R&D cost savings** ({{< var current_drug_approvals_per_year >}}) - {{< var trial_cost_reduction_factor >}} cheaper trials
3. **7-year access acceleration** ({{< var global_annual_infrastructure_damage_communications_conflict >}}) - Earlier treatment access during trials
4. **Research acceleration** ({{< var global_annual_environmental_damage_conflict >}}) - 115X more research capacity (10-20X more breakthroughs)
5. **Rare disease treatments** ({{< var benefit_rare_diseases_annual >}}) - Economically viable orphan drug development for [300M patients](../references.qmd#rare-disease-patients-300m-globally) with diseases lacking treatments ({{< var dfda_trial_completion_rate >}} of {{< var rare_diseases_count_global >}}+ rare diseases have no FDA-approved therapy)
6. **Drug price reductions** ({{< var global_annual_environmental_damage_conflict >}}) - Conservative estimate based on U.S. drug prices {{< var us_drug_price_multiplier_vs_peer_countries >}} higher than peer countries ({{< var us_annual_drug_spending >}} annual U.S. spending; 20-{{< var trial_cost_reduction_pct >}} reduction potential = {{< var drug_price_reduction_savings_low >}}-180B from U.S. alone)
7. **Prevention medicine** ($100.0B) - Based on [global clinical trial market](../appendix/global-clinical-trial-spending-by-phase.qmd) projections exceeding {{< var global_clinical_trial_market_annual >}} annually, enabling economically viable prevention studies
8. **Mental health** ($75.0B) - Conservative partial closure of {{< var sensitivity_peace_dividend_optimistic >}} funding gap identified for global mental health care needs

$$
B_{\text{total}} = 113.6 + 50.0 + 300.0 + 100.0 + 400.0 + 100.0 + 100.0 + 75.0 = \$1,238.6\text{B} \approx \$1.2\text{T}
$$

#### Complete Case ROI

$$
\text{ROI}_{\text{complete}} = \frac{\$1,238.6\text{B annual} \times 10\text{ years}}{\$1.0\text{B implementation}} = 1,239:1
$$

where {{< var dfda_roi_simple >}} is the total annual benefit across all eight categories, 10 years is the NPV-adjusted time horizon, and {{< var peace_dividend_environmental >}} is the total implementation cost. The two largest contributors—**earlier access acceleration** and **research capacity expansion**—are often misunderstood as the same thing. They're not:

- **Earlier Access** = Patients access the SAME treatments 7 years sooner (during trials instead of post-approval)
- **Research Acceleration** = System runs {{< var research_acceleration_multiplier >}}× MORE trials, finding 10-20X MORE breakthroughs

Both are conservative estimates based on proven models ([RECOVERY trial](../appendix/recovery-trial.qmd) costs, disease prevalence data, standard QALY valuations).

### Research Acceleration Mechanism: How We Get {{< var research_acceleration_multiplier >}}×

The {{< var research_acceleration_multiplier >}} research acceleration multiplier is derived from specific, measurable improvements across four dimensions:

**Current System Baseline**:

- {{< var current_trials_per_year >}} clinical trials initiated per year
- [60% completion rate](../appendix/research-acceleration-model.qmd) = **{{< var current_completed_trials_per_year >}} completed trials/year**
- {{< var current_active_trials >}} active trials at any time (3-5 year duration)
- {{< var current_patient_eligibility_rate >}} patient eligibility (5M trial slots for [2.4B people with chronic disease](../references.qmd#disease-prevalence-2-billion))
- {{< var current_trial_abandonment_rate >}} abandonment rate (studies never complete)
- [6-18 months to recruit 100 patients](../appendix/research-acceleration-model.qmd)

**dFDA System Performance**:

- {{< var dfda_trials_per_year_capacity >}} trials/year capacity
- [95% completion rate](../appendix/research-acceleration-model.qmd) = **{{< var dfda_completed_trials_per_year >}} completed trials/year**
- {{< var dfda_active_trials >}} active trials at any time (3-12 month duration)
- {{< var trial_cost_reduction_pct >}} patient eligibility ([1.2B eligible](../appendix/research-acceleration-model.qmd) with minimal exclusions)
- {{< var dfda_trial_abandonment_rate >}} abandonment rate (economic incentives flipped)
- 3 weeks to recruit {{< var traditional_large_trial_size >}} patients

**Multiplier Derivation**:

| Factor | Current | dFDA | Multiplier |
|:---|---:|---:|---:|
| **[Recruitment Speed](../appendix/research-acceleration-model.qmd)** | 6-18 months for 100 patients | 3 weeks for {{< var traditional_large_trial_size >}} patients | **[25x](../appendix/research-acceleration-model.qmd)** |
| **[Trial Completion Speed](../appendix/research-acceleration-model.qmd)** | 3-5 years (perverse incentives) | 3-12 months (aligned incentives) | **[10x](../appendix/research-acceleration-model.qmd)** |
| **[Simultaneous Trials](../appendix/research-acceleration-model.qmd)** | 10,000 active trials | 200,000 active trials | **[20x](../appendix/research-acceleration-model.qmd)** |
| **[Completion Rate](../appendix/research-acceleration-model.qmd)** | 60% finish | 95% finish | **[1.6x](../appendix/research-acceleration-model.qmd)** |
| **Funding Increase** | [$67.5B medical research](../appendix/global-government-medical-research-spending.qmd) | [$94.7B](../appendix/research-acceleration-model.qmd) ($67.5B + {{< var treaty_annual_funding >}}) | **[1.4x](../appendix/research-acceleration-model.qmd)** |

**Theoretical Maximum**:

$$
25 \times 10 \times 1.6 \times 1.4 = 560
$$

This represents **{{< var completed_trials_multiplier_theoretical_max >}}** more completed trials per year

**Conservative Estimate**: {{< var completed_trials_multiplier_actual >}} accounting for real-world friction (ramp-up, adoption, learning curves)

**Used in Analysis**: **{{< var research_acceleration_multiplier >}}** (further conservative adjustment for foundation grant proposal credibility)

This represents:

- From {{< var current_completed_trials_per_year >}} completed trials/year → [227,700 completed trials/year](../appendix/research-acceleration-model.qmd) ({{< var research_acceleration_multiplier >}}x)
- From [50 drug approvals/year](../references.qmd#global-new-drug-approvals-50-annually) → 1,000-{{< var dfda_drug_approvals_per_year_high >}} approvals/year (20-40x)
- From [$41,000 cost per patient](../appendix/recovery-trial.qmd) → {{< var recovery_trial_cost_per_patient >}}-1,000 cost per patient ([82x cost reduction](../appendix/recovery-trial.qmd), proven by Oxford RECOVERY trial)

**For detailed analysis including the 7-year access model, research capacity calculations, benefit breakdown table, and sanity checks**, see [Research Acceleration Model - Detailed Analysis](../appendix/research-acceleration-model.qmd).

# Personal Economic Impact: From Societal to Individual

The aggregate societal benefits ({{< var combined_peace_health_dividends_annual_for_roi_calc >}}-{{< var total_complete_benefits_annual >}} annually) result from individual economic gains multiplied across billions of people. Understanding individual impact helps explain both the scale and the equity of the Disease Eradication Model.

{{< include ../figures/disease-eradication-annual-benefits-stacked-area-chart.qmd >}}

For detailed analysis of personal wealth calculations, see [Disease Eradication Model: Personal Lifetime Wealth](../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd).

# Problem Statement and Opportunity Cost

### Current Resource Allocation

Global spending on health-related challenges demonstrates significant misalignment between resource allocation and burden of disease (see [Humanity's Budget](../appendix/humanity-budget-overview.qmd) for complete breakdown):

- **Military spending**: {{< var victory_bond_annual_payout >}} trillion annually ([40X](../appendix/humanity-budget-overview.qmd) [medical research funding](../appendix/global-government-medical-research-spending.qmd))
- **Symptomatic disease treatment**: {{< var global_symptomatic_disease_treatment_annual >}} annually (primarily managing chronic conditions rather than curative interventions)
- **Economic burden of disease**: {{< var global_disease_economic_burden_annual >}} annually in lost productivity, premature mortality, and disability-adjusted life years
- **Total annual cost**: {{< var global_total_health_and_war_cost_annual >}}

**Current investment in curative research**:

- Global government medical research: {{< var global_med_research_spending >}} billion annually

$$
\frac{\$68\text{B}}{\$128.6\text{T}} = 0.053\% \text{ of total disease burden}
$$

- Disease eradication achievements: Zero in past 50 years (since [smallpox, 1980](../references.qmd#smallpox-eradicated))
- Resource allocation ratio: 1:40 (medical research : military spending)

{{< include ../figures/military-vs-medical-research-spending-1-percent-treaty-column-chart.qmd >}}

### Mortality and Morbidity Burden

<!-- !Annual deaths from disease ({{< var global_annual_deaths_curable_diseases >}}) versus deaths from 9/11 Terrorist Attacks (2,996) -->

The World Health Organization reports {{< var global_daily_deaths_curable_diseases >}} daily deaths from preventable or potentially curable diseases ([54.75 million annually](../references.qmd#who-daily-deaths)). This mortality burden exceeds:

- [Annual terrorism deaths](../references.qmd#chance-of-dying-from-terrorism-1-in-30m) by a factor of {{< var disease_vs_terrorism_deaths_ratio >}}

$$
\frac{54.75\text{M disease deaths}}{3{,}000\text{ terrorism deaths}} \approx 18{,}274:1
$$

- [Annual war deaths](../references.qmd#acled-active-combat-deaths) by a factor of 137:1 (based on {{< var global_annual_conflict_deaths_total >}} conflict deaths annually)

$$
\frac{54.75\text{M disease deaths}}{400{,}000\text{ conflict deaths}} \approx 137:1
$$

Despite this disparity in mortality burden, resource allocation heavily favors security spending over medical research and curative interventions.

# How This Compares to History

### Better Than the Best Charities

Here's how it compares to the most effective charities in the world ([GiveWell top charities](../references.qmd#givewell-cost-per-life-saved)):

| Intervention | Cost to Achieve Outcome | This Initiative's Equivalent |
| :--- | :--- | :--- |
| **[GiveWell Top Charities](../references.qmd#givewell-cost-per-life-saved)** (e.g., Against Malaria Foundation) | Spend **~`{python} givewell_cost_per_life_min_formatted` - `{python} givewell_cost_per_life_max_formatted`** to save one life | Generate **{{< var global_dfda_qalys_gained_annual >}} QALYs** annually while creating **{{< var dfda_npv_net_benefit_conservative >}}** in net economic value |

**The Difference**: GiveWell's charities are the best ways to spend money to save lives. They cost money but save lives very efficiently.

This plan doesn't cost money, it *makes* money while saving lives. Instead of asking people to donate, it makes everyone richer while curing diseases.

**Bottom line**: While the world's best charities spend `{python} givewell_cost_per_life_min_formatted`-`{python} givewell_cost_per_life_max_formatted` to save a life (which is excellent), the {{< var treaty_reduction_pct >}} Treaty + DIH + dFDA actually **SAVES society `{python} cost_per_life_investor_funded_formatted` per life saved**.

{{< include ../figures/health-interventions-roi-comparison-column-chart.qmd >}}

### Better Than History's Best Public Health Wins

| Intervention | How it Creates Value | Scale of Annual Net Benefit |
| :--- | :--- | :--- |
| **[Childhood Vaccinations](../references.qmd#childhood-vaccination-roi)** | Prevents immense long-term treatment costs for diseases like measles and polio | Billions to Tens of Billions |
| **Smoking Cessation** | Prevents expensive chronic diseases (cancer, heart disease) through low-cost interventions | Billions to Tens of Billions |
| **[Water & Sanitation](../references.qmd#clean-water-sanitation-roi)** | Avoids disease costs for entire populations at low cost | Hundreds of Millions to Billions |
| **[1% Treaty (Peace Dividend)](../appendix/peace-dividend-calculations.qmd)** | Reduces global conflict costs by 1%, creating massive economic benefit | **~{{< var peace_dividend_annual_societal_benefit >}}, Annually** |
| **[dFDA (R&D Efficiency)](../appendix/dfda-cost-benefit-analysis.qmd)** | Makes clinical research ~{{< var trial_cost_reduction_factor >}}× more efficient, unlocking huge R&D savings | **~$50.0B, Annually** |

#### Why This Is Different

Vaccines and smoking cessation programs are amazing, they solve specific problems with a high return.

The {{< var treaty_reduction_pct >}} Treaty and dFDA initiative tackles two problems at once:

1. **The Peace Dividend** is a massive economic gain on par with the largest public health wins, created simply by reducing a global negative (conflict)
2. **The dFDA** then uses a tiny fraction of that gain to fix the *system* of medical research, generating a *second* massive win

Instead of solving one problem, this uses a global-scale win to fund a system-scale win. When you redirect the world's largest source of waste to fund its most impactful opportunity, the math gets wild.

### 10X Larger Than Childhood Vaccinations

{{< include ../figures/health-programs-vs-1-percent-treaty-societal-benefits-bar-chart.qmd >}}

The conservative case annual economic benefit of {{< var combined_peace_health_dividends_annual_for_roi_calc >}} significantly exceeds the most successful public health programs in history. Comparing to [childhood vaccination programs](../references.qmd#childhood-vaccination-roi) (estimated [10-20B annual global benefit](../references.qmd#childhood-vaccination-roi) from preventing measles, polio, etc.):

$$
\text{Relative Scale} = \frac{\$163.6\text{B}}{\sim\$15\text{B}} \approx 11:1
$$

where {{< var combined_peace_health_dividends_annual_for_roi_calc >}} is the [1% Treaty conservative case benefit](../appendix/dfda-cost-benefit-analysis.qmd) and $15B is the estimated [childhood vaccination annual benefit](../references.qmd#childhood-vaccination-roi).

This makes the {{< var treaty_reduction_pct >}} Treaty/dFDA system **[11X larger in economic impact](../appendix/intervention-comparison-table.qmd)** than childhood vaccinations, one of the most successful public health interventions ever implemented.

Unlike traditional interventions that require ongoing charitable funding, the 1% Treaty is **self-funding**: it generates {{< var combined_peace_health_dividends_annual_for_roi_calc >}} in annual economic surplus (conservative case) to sustain operations and expansion without requiring ongoing charitable contributions.

---

# Who Benefits and How

The {{< var treaty_reduction_pct >}} Treaty creates positive economic incentives across all major groups, eliminating traditional opposition to healthcare system reform. This alignment makes it politically feasible and sustainable.

**Who Gets What** (see [Aligning Incentives](../solution/aligning-incentives.qmd) for details):

- **Defense sector**: Keeps {{< var defense_sector_retention_pct >}} of current budget 
- **Pharmaceutical industry**: Trial costs shift from expense to revenue (patients fund participation); [research capacity increases 115X](../appendix/research-acceleration-model.qmd)
- **Insurance companies**: Net savings from [reduced disease burden](../references.qmd#disease-economic-burden-109t) ({{< var global_disease_economic_burden_annual >}} current economic cost)
- **Healthcare providers**: More treatment options; [earlier access to effective therapies](../appendix/economic-value-of-accelerated-treatments.qmd)
- **Patients**: Access to clinical trials as healthcare and new treatments years or decades sooner
- **Taxpayers**: Net reduction in taxes and healthcare costs through improved R&D efficiency

See [Aligning Incentives](../solution/aligning-incentives.qmd) for detailed analysis and implementation strategy.

# Implementation Strategy

The economic benefits outlined above demonstrate the value proposition of the {{< var treaty_reduction_pct >}} Treaty system. Implementation requires political mobilization to achieve treaty adoption:

**For comprehensive implementation details**, see:

- **[Campaign Budget](campaign-budget.qmd)** - Detailed breakdown of political mobilization costs
- **[VICTORY Social Impact Bonds](victory-bonds.qmd)** - Financing mechanism for lobbying efforts
- **[Financial Plan Overview](financial-plan.qmd)** - Complete fundraising, spending, and treasury management framework

### Campaign Budget Breakdown

The [$1.0B campaign cost](campaign-budget.qmd) (used as denominator in complete case {{< var roi_all_direct_benefits >}}:1 ROI) allocates funds across seven strategic categories:

| Budget Category | Amount | Purpose |
|:---|---:|:---|
| **[Viral Referendum](campaign-budget.qmd)** | {{< var treaty_campaign_budget_viral_referendum >}} | Global direct democracy campaign, social media amplification, petition platforms |
| **[AI-Assisted Lobbying](campaign-budget.qmd)** | {{< var treaty_campaign_budget_technology >}} | Automated legislative outreach, personalized constituent messaging, political mapping |
| **[Technology Platform](campaign-budget.qmd)** | {{< var treaty_campaign_budget_technology >}} | Voting infrastructure, transparency systems, wishocracy implementation |
| **[Legal & Compliance](campaign-budget.qmd)** | {{< var treaty_campaign_budget_partnerships >}} | International treaty law, regulatory compliance, jurisdictional coordination |
| **[Partnerships](campaign-budget.qmd)** | {{< var treaty_campaign_budget_partnerships >}} | Coalition building with NGOs, medical organizations, patient advocacy groups |
| **[Operations](campaign-budget.qmd)** | {{< var treaty_campaign_budget_reserve >}} | Campaign management, communications, logistics, staffing |
| **[Reserve](campaign-budget.qmd)** | {{< var treaty_campaign_budget_reserve >}} | Contingency for unforeseen challenges and opportunities |
| **Total Campaign Cost** | **{{< var treaty_campaign_total_cost >}}** | 4-year implementation timeline (amortized: {{< var treaty_campaign_budget_technology >}}/year) |

This budget is designed for a 3-5 year campaign to achieve treaty ratification by major powers, representing less than 4% of the first year's conservative benefits ({{< var combined_peace_health_dividends_annual_for_roi_calc >}}). The campaign cost is a one-time investment with perpetual returns, as the system becomes self-sustaining through the captured peace dividend.

This economic analysis focuses on the return on investment once the system is operational, demonstrating that the intervention generates 463:1 to {{< var roi_all_direct_benefits >}}:1 returns regardless of the specific path to adoption.

# Detailed Technical References

For the rigorous analysis:

- **[dFDA Cost-Benefit Analysis](../appendix/dfda-cost-benefit-analysis.qmd)** - The complete {{< var roi_dfda_savings_only >}} ROI breakdown with NPV calculations
- **[Health Dividend](health-dividend.qmd)** - Accessible overview of the {{< var roi_dfda_savings_only >}} ROI
- **[Economic Value of Accelerated Treatments](../appendix/economic-value-of-accelerated-treatments.qmd)** - The 7-year access acceleration math
- **[Economic Models Notebook](../economics/economic_models.ipynb)** - All calculations you can verify yourself
- **{{< var treaty_reduction_pct >}} Treaty Cost-Effectiveness** - Why this is a dominant health intervention

# Risk Analysis and Mitigation

### Implementation Risks

**Political Risk**: Treaty adoption requires coordination across multiple national governments

- *Mitigation*: Dual-track approach combining grassroots referendum with diplomatic engagement (see [Treaty Adoption Strategy](../strategy/treaty-adoption-strategy.qmd))
- *Precedent*: Historical military spending reductions have occurred during periods of public mobilization (post-WW2, post-Cold War)

**Technical Risk**: dFDA platform development and scaling challenges

- *Mitigation*: Phased rollout beginning with proven platforms (similar to RECOVERY trial model); open-source architecture enabling distributed development
- *Validation*: Oxford [RECOVERY trial](../appendix/recovery-trial.qmd) demonstrated 82x cost reduction at scale (11,000+ participants, 6 treatment arms, {{< var dfda_opex_regulatory >}} total cost)

**Adoption Risk**: Insufficient patient enrollment in decentralized trials

- *Mitigation*: Economic incentives (free treatment + compensation); improved trial accessibility; democratized research priorities
- *Evidence*: Current clinical trial participation ({{< var current_clinical_trial_participation_rate >}} of population) limited by access barriers, not willingness

**Financial Risk**: Insufficient funding to achieve referendum threshold and political mobilization

- *Mitigation*: Multi-stage fundraising with milestone-based releases; diversified funding sources; assurance contracts
- *Conservative threshold*: [280M votes](../references.qmd#3-5-rule) ({{< var global_population_activism_threshold_pct >}} of global population) through viral referendum mechanics

See [Investor Risk Analysis](../appendix/investor-risk-analysis.qmd) for complete risk assessment and sensitivity analysis.

### Governance and Accountability

**DIH Treasury Governance**: [Wishocratic system](../solution/wishocracy.qmd) enabling democratic allocation of research funding

- [8 billion potential participants](../solution/wishocracy.qmd) (any human) vs. current centralized decision-making ([200 NIH staff](../references.qmd#nih-decision-makers-200-people))
- Quadratic voting mechanism prevents plutocratic capture
- Transparent, auditable allocation via blockchain-based system

**dFDA Platform Governance**: Decentralized autonomous organization (DAO) structure

- Open-source protocols ensuring transparency and reproducibility
- Distributed validation preventing single-point failures
- Regulatory compliance framework integrating with national authorities

**Financial Accountability**: Independent oversight and reporting

- Annual third-party audits of DIH treasury and dFDA operations
- Public reporting of all expenditures and outcomes
- Milestone-based funding releases tied to measurable objectives

See [Governance Framework](../appendix/governance.qmd) and [Legal Compliance Framework](../appendix/legal-compliance-framework.qmd) for complete governance structures.

---

# Limitations and Uncertainties

This analysis acknowledges several important limitations and sources of uncertainty inherent in modeling a transformative policy intervention of this scale.

## Model Assumptions and Constraints

### Adoption Timeline Uncertainty

The base case assumes gradual adoption over {{< var dfda_npv_adoption_ramp_years >}} years to full implementation. Actual adoption may be faster or slower depending on:

- **Regulatory harmonization:** International coordination requirements may extend implementation timelines
- **Technical infrastructure readiness:** EHR interoperability, data standardization, and privacy compliance vary significantly across jurisdictions
- **Stakeholder acceptance:** Pharmaceutical industry, regulatory bodies, and healthcare providers may resist or accelerate adoption based on perceived incentives

**Sensitivity analysis addresses this:** Worst-case scenario models extended timelines with ROI remaining positive (66:1) even under pessimistic assumptions.

### Cost Reduction Assumptions

The {{< var trial_cost_reduction_pct >}} baseline R&D cost reduction derives from the Oxford RECOVERY trial's demonstrated {{< var trial_cost_reduction_factor >}}× efficiency gain. However:

- **Trial complexity variation:** The RECOVERY trial focused on repurposed drugs for acute conditions; novel therapeutics for chronic diseases may not achieve equivalent cost reductions
- **Regulatory requirements:** Some trial phases (particularly safety studies) may retain higher costs regardless of decentralization
- **Geographic variation:** Cost reductions may be greater in high-cost jurisdictions (U.S., Europe) and lower in regions with already-efficient trial systems

**Conservative approach:** Analysis uses {{< var trial_cost_reduction_pct >}} reduction (midpoint) rather than the demonstrated 95%+ efficiency gains, providing substantial margin of safety.

### QALY Calculation Uncertainties

The {{< var global_dfda_qalys_gained_annual >}} annual QALY estimate aggregates three benefit streams with varying levels of empirical support:

**Stream A (Accelerated Drug Access):** High confidence, based on well-documented costs of delayed access (84,000 life-years lost per year delay in cancer therapies alone). However:
- Assumes pipeline drugs would eventually reach approval under current system
- Does not account for reduced efficacy if treatments reach patients in later disease stages

**Stream B (Prevention via Real-World Evidence):** Medium confidence, preventative care benefits are well-established, but scale of improvement from comprehensive data remains uncertain:
- Adherence improvements may be smaller than projected
- Selection bias in opt-in populations could limit generalizability

**Stream C (Rare Disease Treatments):** Lower confidence, economic viability of rare disease research is theoretically sound but empirically unproven at scale:
- Assumes cost reductions make trials economically viable
- Actual success rates for rare disease therapies remain uncertain

**Conservative approach:** Base case uses median estimates across all three streams; sensitivity analysis demonstrates positive returns even at conservative QALY levels ({{< var qalys_total_conservative >}} annually yields 66:1 ROI).

## Data Limitations

### Military Spending Data

Global military expenditure data (${{< var global_military_spending_annual_2024 >}}B, SIPRI 2024) is well-documented but:

- **Off-budget spending:** Some military expenditures may be classified or categorized elsewhere
- **Exchange rate fluctuations:** Multi-year projections require currency assumptions
- **Conflict zones:** Military spending in active conflict regions may be less fungible for redirection

### Clinical Trial Market Sizing

The ${{< var global_clinical_trials_spending_annual >}} global clinical trials market estimate derives from industry reports, which:

- **Industry variation:** Methodologies vary across market research firms
- **Private vs. public trials:** Some trial spending may be unreported or proprietary
- **Non-pharmaceutical trials:** Medical device and digital health trials may have different cost structures

### QALY Valuation Thresholds

Standard willingness-to-pay thresholds (${{< var qalys_from_prevention_conservative >}}-${{< var standard_economic_qaly_value_usd >}} per QALY) vary by jurisdiction:

- **Geographic variation:** WHO recommends 1-3× GDP per capita; high-income countries use higher thresholds
- **Ethical considerations:** Monetary QALY valuations raise equity concerns
- **Discount rates:** Future health benefits discounted at {{< var npv_discount_rate_standard >}} may undervalue long-term gains

## Generalizability Constraints

### Political Feasibility

This analysis models economic returns conditional on treaty ratification. Political feasibility depends on:

- **Geopolitical stability:** International cooperation requirements may face challenges during periods of global tension
- **Domestic politics:** Military budget reductions face constituency resistance in defense-dependent regions
- **Lobbying influence:** Defense industry opposition may impede adoption

**Risk assessment:** The 1% reduction is intentionally modest to minimize political resistance. Historical precedents (military-to-civilian conversions post-Cold War) demonstrate feasibility.

### Institutional Capacity

Implementation requires substantial institutional development:

- **Regulatory expertise:** dFDA requires experienced personnel (FDA, EMA, other regulators)
- **Technical infrastructure:** Data systems, AI/ML capabilities, cybersecurity at global scale
- **Legal frameworks:** International treaties, data privacy compliance, intellectual property harmonization

**Mitigation:** Phased implementation allows capacity building concurrent with scale-up.

### Healthcare System Integration

Benefits assume integration with existing healthcare infrastructure:

- **EHR interoperability:** U.S. and other jurisdictions still face significant interoperability challenges
- **Wearable adoption:** Real-world data collection requires widespread wearable/digital health adoption
- **Provider participation:** Clinician buy-in necessary for trial recruitment and data quality

## Uncertainty Quantification

### Primary Risk Factors

The following table summarizes key risk factors and their mitigation strategies:

| Risk Factor | Level | Primary Uncertainty | Mitigation Strategy |
|:---|:---:|:---|:---|
| **Political Risk** | VERY HIGH | Treaty ratification dependent on international coordination | Modest 1% reduction; precedent from military-industrial lobbying ROI (1,813:1) |
| **Execution Risk** | HIGH | Complex global legal/technical coordination required | Phased implementation; leverage existing regulatory expertise |
| **Regulatory Risk** | MEDIUM-HIGH | Harmonization across jurisdictions varies | Pilot programs in willing jurisdictions first |
| **Market Risk** | VERY LOW | ${{< var global_military_spending_annual_2024 >}}T military spending already allocated | Redirection rather than new appropriation |
| **Technical Risk** | MEDIUM | Data interoperability, AI/ML accuracy | Build on proven platforms (Medable $521M raised, $2.1B valuation) |

### Scenario Analysis Robustness

Comprehensive sensitivity analysis across multiple scenarios demonstrates:

- **Worst-case (66:1 ROI):** Benefits half as good, costs twice as high, intervention remains highly cost-effective
- **Conservative (463:1 ROI):** R&D savings only, excludes peace dividend, intervention is dominant
- **Complete (1,239:1 ROI):** All quantifiable benefits, intervention transforms global health economics

**Key insight:** Even under pessimistic assumptions with multiple adverse conditions simultaneously occurring, the intervention generates positive returns exceeding most established public health programs.

## External Validity Considerations

### Transferability Across Contexts

This analysis models global implementation. Results may vary by:

- **Income level:** High-income countries may see greater cost reductions (trials more expensive); low-income countries may see greater health gains (larger disease burden)
- **Disease profiles:** Communicable disease contexts (prevalent in low-income settings) vs. chronic disease contexts (prevalent in high-income settings) may yield different QALY gains
- **Regulatory maturity:** Countries with established regulatory frameworks may implement faster

### Temporal Validity

Projections use 2024 baseline data. Secular trends may affect outcomes:

- **Medical technology advancement:** AI/ML capabilities improving rapidly; may enhance or diminish relative dFDA advantages
- **Geopolitical shifts:** Global military spending trends dependent on international relations
- **Healthcare costs:** Rising healthcare expenditures may increase baseline benefits; cost controls may decrease them

## Limitations Summary

Despite these limitations, several factors support the analysis's robustness:

1. **Conservative assumptions throughout:** Base case uses median estimates; optimistic scenarios excluded from primary ROI ({{< var roi_dfda_savings_only >}}:1)
2. **Empirical grounding:** Cost reductions based on demonstrated RECOVERY trial results, not theoretical models
3. **Sensitivity analysis:** Wide range of scenarios tested; positive returns maintained across all plausible parameter combinations
4. **Dominant intervention status:** Negative ICER (-$59,476/QALY) means intervention saves money even if health benefits are substantially overstated

**Transparency commitment:** All parameters, data sources, and calculation methodologies are publicly documented with confidence levels and last-update dates in [Parameters and Calculations Reference](../appendix/parameters-and-calculations.qmd) and [References](../references.qmd).

Future research priorities include prospective data collection during pilot implementations, real-world validation of cost reduction estimates, and longitudinal assessment of QALY gains across diverse populations and disease contexts.

---

# Conclusion

This economic analysis demonstrates that redirecting 1% of global military spending to medical research through the Decentralized Institutes of Health and Decentralized FDA system generates return on investment ranging from 463:1 (conservative estimate) to {{< var roi_all_direct_benefits >}}:1 (complete estimate), depending on analytical scope.

**Key Findings**:

- **Self-funding structure**: Zero net new spending required (funds redirected from existing military budgets)
- **Dominant intervention**: Simultaneously reduces costs and improves health outcomes
- **Conservative ROI**: {{< var roi_dfda_savings_only >}} based solely on R&D efficiency gains

$$
\frac{\$249.3\text{B NPV benefit}}{\$538\text{M NPV cost}} = 463:1
$$

(see [dFDA Cost-Benefit Analysis](../appendix/dfda-cost-benefit-analysis.qmd))

- **Complete ROI**: {{< var roi_all_direct_benefits >}}:1 including all eight quantifiable benefit categories ({{< var total_complete_benefits_annual >}} annual benefit)
- **Lives saved**: {{< var treaty_total_lives_saved_annual >}} annually at net societal benefit of [$6.56M per life](../appendix/1-percent-treaty-cost-effectiveness.qmd)
- **Political feasibility**: Positive economic incentives across all major stakeholder groups

**Comparative Context**: This intervention rivals or exceeds the cost-effectiveness of history's most successful public health achievements (see [Intervention Comparison Table](../appendix/intervention-comparison-table.qmd) for detailed ROI comparisons including smallpox eradication and childhood vaccinations) while requiring no ongoing charitable funding.

**Implementation Pathway**: Phased approach beginning with global referendum and political mobilization, proceeding through treaty adoption, DIH establishment, and dFDA deployment over [36 months](../strategy/roadmap.qmd) (see [Roadmap](../strategy/roadmap.qmd) for complete implementation timeline).

The economic case is grounded in conservative assumptions, validated against peer-reviewed evidence (particularly the [Oxford RECOVERY trial](../appendix/recovery-trial.qmd)), and subjected to comprehensive [sensitivity analysis](../appendix/1-percent-treaty-cost-effectiveness.qmd). The methodology employs standard health economics frameworks (NPV, QALYs, ICER) to enable comparison with existing interventions and facilitate foundation grant evaluation processes.

---

# References

For complete bibliography, data sources, and citations, see:

- **[References](../references.qmd)** - Comprehensive bibliography of all cited sources
- **[Parameters and Calculations Reference](../appendix/parameters-and-calculations.qmd)** - Complete documentation of all 422 parameters with LaTeX equations, confidence indicators, and source attribution
- **[Data Sources](../appendix/parameters-and-calculations.qmd#sec-external)** - 130 external parameters from peer-reviewed sources
- **[BibTeX Export](../../references.bib)** - 94 unique citations in BibTeX format for LaTeX submissions

All data, computational code, and analysis methods are publicly available in the project [GitHub repository](https://github.com/FDA-AI/FDAi/).